Vita Coco (COCO) Insider: Option Exercise at $10.178 and $40 Sale Reported
Rhea-AI Filing Summary
Charles van Es, Chief Sales Officer of Vita Coco Company, Inc. (COCO), reported transactions dated 09/12/2025 on Form 4. He exercised a stock option to acquire 10,000 shares at an exercise price of $10.178 per share and simultaneously sold 10,000 shares under a Rule 10b5-1 plan at a weighted average price of $40.002 per share. After these transactions his beneficial ownership is reported as 84,328 shares. The filing itemizes multiple outstanding non-qualified stock options with exercise prices ranging from $10.178 to $33.36 and various vesting schedules; some options are fully vested and exercisable. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/16/2025.
Positive
- Exercise and sale executed transparently: Sale reported as made pursuant to a Rule 10b5-1 trading plan.
- Realized spread disclosed: Exercise price of $10.178 and weighted average sale price of $40.002 for 10,000 shares, explicitly reported.
- Clear option schedule: Multiple non-qualified stock options and vesting schedules are itemized, improving disclosure of potential future dilution.
Negative
- Reduction in insider holdings: Beneficial ownership decreased by 10,000 shares to 84,328 shares following the sale.
- Outstanding option pool remains: Significant numbers of options remain exercisable or subject to future vesting, which could lead to dilution if exercised.
Insights
TL;DR: Officer exercised options at $10.178 and sold shares at ~$40.00 via a 10b5-1 plan, reducing holdings but realizing a material spread.
The reported exercise and concurrent sale are typical compensation monetization events. The exercise price of $10.178 and weighted average sale price of $40.002 are explicitly stated, indicating a significant per-share spread between exercise and sale prices for the 10,000 shares transacted. The filing also discloses a portfolio of outstanding non-qualified options with staggered vesting and expiration dates, which could lead to future option exercises and potential share issuances if exercised. No new material corporate developments or changes in control are reported.
TL;DR: Transactions follow standard insider protocols, with sales executed under a Rule 10b5-1 plan and attorney-in-fact signature on the Form 4.
The sale being executed pursuant to a Rule 10b5-1 trading plan and the Form 4 being signed by counsel are both procedural safeguards that reduce concerns about opportunistic insider trading. The filing clearly lists vesting schedules for multiple option grants, including several fully vested options, providing transparency on future potential insider issuance. No departures, repricings, or unusual governance actions are disclosed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $10.178 | $102K |
| Sale | Common Stock | 10,000 | $40.002 | $400K |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.03, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The stock option is fully vested and currently exercisable. The stock option is fully vested and currently exercisable. The stock option vests in four equal annual installments beginning on November 27, 2022. The stock option vests in three equal annual installments beginning on August 15, 2025. The stock option vests in four equal annual installments beginning on March 10, 2024. The stock option vests in four equal annual installments beginning on March 4, 2025. The Reporting Person was granted stock options that will vest in four annual equal installments on each anniversary of the grant date provided that the Reporting Person remains in continuous service on each vesting date.
